Life Biosciences announced it treated the first participant in a clinical trial testing whether activation of three genes can partially "reprogram" aging eye cells toward a younger state. The trial, reported by Nature, targets glaucoma and plans to enroll up to 12 patients. Animal studies show promise, but scientists warn of risks such as potential cancer development, and the company stresses the work focuses on treating disease rather than extending lifespan.
First Human Treated in Trial Testing Gene 'Reprogramming' to Rejuvenate Eye Cells
Scientists test first-ever therapy to make human cells young again
Scientists have treated the first participant in a clinical trial that tests whether aging human eye cells can be partially "reprogrammed" to behave more like younger cells. The study, reported by Nature, is exploring a potential therapy for glaucoma — a leading cause of irreversible blindness that damages the optic nerve.
The experimental approach temporarily activates three genes to induce partial cell reprogramming. Unlike full reprogramming, which can erase a cell’s identity, this partial method aims to push older eye cells toward a younger state while preserving their function as retinal and optic nerve cells.
Trial Details and Goals
Life Biosciences, a Boston-based biotech company, announced on June 9 that it had treated the first participant. The Phase 1 study plans to enroll up to 12 people with glaucoma and may later expand to patients with related optic nerve or age-related eye conditions. The primary objectives are safety and signals of biological effect rather than proving a cure at this stage.
Preclinical Evidence and Risks
Animal studies indicate that partial cell reprogramming can rejuvenate cell function without obvious short-term complications, and researchers hope the approach could promote regeneration of optic nerve neurons that normally do not regrow after injury.
Scientific Caution: Experts warn this technique carries potential risks, including the theoretical possibility that altered cells could become cancerous if reprogramming is not precisely controlled.
Life Biosciences emphasizes that its work is focused on treating specific age-related diseases rather than pursuing whole-body rejuvenation or lifespan extension. Chief Scientific Officer Sharon Rosenzweig-Lipson told Scientific American the company is proceeding disease by disease to assess safety and therapeutic potential.
As with all early-stage trials, results in humans are uncertain. Researchers say careful monitoring and staged clinical testing will be critical to determine whether the approach is safe and effective for patients with glaucoma.
Help us improve.
